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Abstract
It is crucial to develop new antischistosomal drugs since there is no vaccine and the whole world is relying on only
a single drug for the treatment of schistosomiasis. One of the obstacles to the development of drugs is the
absence of the high throughput objective screening methods to assess drug compounds efficacy. Thus for
identification of new drug compounds candidates, fast and accurate in vitro assays are unavoidable and more
research efforts in the field of drug discovery can target schistosomula. This review presents a substantial overview
of the present state of in vitro drug sensitivity assays developed so far for the determination of anti-schistosomula
activity of drug compounds, natural products and derivatives using newly transformed schistosomula (NTS). It
highlights some of the challenges involved in in vitro compound screening using NTS and the way forward.
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Background
Hundreds of millions of people are living at risk of schis-
tosomiasis infection [1]. More than 207 million people are
infected worldwide with 85% living in Africa. This makes
schistosomiasis one of the most devastating tropical dis-
eases in the world and remains a major source of morbid-
ity and mortality for developing countries, especially in
Sub-Saharan Africa [1]. Also known as “snail fever”, schis-
tosomiasis is a water-borne trematodiasis carried by fresh
water snails infected with one of the five varieties of the
parasite Schistosoma. But three principal varieties are
mainly the causative agents for human schistosomiasis:
Schistosoma mansoni, Schistosoma haematobium and
Schistosoma japonicum. The pathophysiology associated
with schistosomiasis, is mainly due to immune response
to the schistosome eggs that are trapped in tissues and or-
gans. The liver, intestines and bladder usually trap eggs on
their way out of the host. The spleen, as a lymphoid organ,
becomes enlarged (splenomegaly) and together with the
enlargement of the liver result in hepatosplenomegaly.
Schistosomiasis has both an acute and a chronic phase.
Acute schistosomiasis are generally short-term and mild
and can develop a few weeks after the schistosome
parasite first penetrates into the skin of the host. But if left
untreated, schistosomiasis cause by any of the three spe-
cies listed above may become a chronic inflammation
which develops slowly into swelling, fibrosis and necrosis
of the affected tissues such as intestinal organs, the liver
and the bladder, as well as a wide range of other symp-
toms which gradually damage the host physiologically and
even cognitively [2, 3].
Mass drug administration (MDA) in endemic areas
using praziquantel (PZQ) remains a major cornerstone
of schistosomiasis control programs [4]. Praziquantel
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was discovered in the year 1970’s and brought to the
market in 1988 under the name Biltricide [5, 6]. It is so
far the only drug available and recommended by World
Health Organization (WHO) for the treatment of schis-
tosomiasis. This single drug PZQ, is used for the treat-
ment of millions of people annually and as stated in the
recent publications, its coverage is projected to reach
235 million people by 2018, which raises concerns of in-
creasing drug pressure [7, 8]. Furthermore, although
there are several advantages of this drug, in particular its
high efficacy on the adult worms of all the medically im-
portant Schistosoma species and its excellent tolerability,
PZQ has some disadvantages, mostly its inefficiency
against younger stage of schistosomes [9]. This mean
that treatment does not rule out all the worms in those
who are infected and necessitates the repeat of the treat-
ment. Again, reliance on a single drug as the sole treat-
ment, while positively reducing morbidity has led to big
concerns over development of potential drug resistance
[10]. These facts emphasize the imperative to search for
the next generation of antischistosomal drugs. There-
fore, a number of studies have recommended repeatedly
the need for novel drugs, since the drug discovery and
development pipeline is virtually dry [11]. Only a few
candidates compounds have been studied in preclinical
phases [12] and none of them have reached the clinical
trials phase. For instance, the target product profile for a
new antischistosomal drug [12] was not met by meflo-
quine and artemisinins [13, 14].
Formerly, procedures established at TDR-designated
compound screening centers relied on adult worms in-
cubated with the candidate drugs for 72 h [15]. Follow-
ing the incubation period, the parasite viability was
assessed microscopically [15]. This approach of in vitro
drug screening based on the phenotype of the whole
adult worm organism usually requires the intensive use
of laboratory animals (hamster, rats, mice) since there is
no existing in vitro life cycles for Schistosoma. This ap-
proach is also time consuming and low-throughput and
relied on a small number of research groups experts that
are able to handle the complex life cycle of Schistosoma
and work with both high recovery of adult parasite from
mammalian host and long screen timelines. The latter is
the consequence of the long period that Schistosoma in-
fection requires to become obvious since in the mouse
model, it may take not less than 30 days for S. mansoni
infections to become patent [16] and even more than
30 days for others specie such as S. haematobium.
Not long ago, the screening method using Newly Trans-
formed Schistosomula (NTS) has been popularised as a
higher-throughput [17–20]. Here, we have provided an
overview for the alternative approach to phenotypic
screening younger parasites that can be easily obtained
from the intermediary host snails and in greater numbers
than adult worms. This review presents the current state
of in vitro drug sensitivity assays developed so far for the
determination of anti-schistosomula activity of drug com-
pounds, natural products and derivatives using NTS and
highlights some of the challenges involved in in vitro com-
pound screening using NTS.
In which stage of the Schistosoma life cycle is
schistosomula found?
Schistosomes have a complex life cycle (Fig. 1). The
transmission of schistosomiasis occurs when people har-
boring the parasite contaminate freshwater sources
(lakes, ponds, rivers and dams) inhabited by snails with
their urine (for urogenital Schistosomiasis) or faeces (for
intestinal schistosomiasis) containing parasite eggs.
Under optimal conditions the fertilized eggs hatch in
water and miracidia are released. Once released from
the eggs, miracidia swim in the fresh water and pene-
trate specific intermediate snail hosts. In the snail host,
the miracidiae multiply by asexual division of 2 genera-
tions of sporocysts (primary and then secondary sporo-
cysts) and produce cercariae from 4 to 6 weeks [21, 22].
Upon release from the snail, the infective cercariae can
remain infective in freshwater for 1 to 3 days [22]. They
swim in the water in search of the definitive host. Upon
contact with the host, cercariae penetrate the skin of the
host, and lose their bifurcated tail to become schistoso-
mulae [22]. It takes several days for the schistomules to
move from the skin into the venous circulation then into
the lungs [22]. This path generally takes within 5 to
7 days after penetration. The schistosomulae takes at
least 15 days to travel through the circulatory system to
the hepatoportal circulation where they grow and ma-
ture into adult worms and pair up. In humans, adult
worms are found to reside in either the perivesicular or
mesenteric venules in various locations. This seems to
be specific for each species. Specifically, S. japonicum
occurs frequently in the superior mesenteric veins drain-
ing the small intestine while S. mansoni is frequently
found in the superior mesenteric veins draining the large
intestine. Nevertheless, S. japonicum and S. mansoni can
occupy either location, and they are capable of moving
between both sites, therefore it is impossible to state un-
equivocally that one species is specifically found in one
location. Generally, S. haematobium is found in the ven-
ous plexus of the bladder, but can sometime be found in
the rectal venules. The females start laying eggs from 4
to 6 weeks after infection in their final infection site
which is either the bladder or the intestine. This usually
continues for 3 to 5 years equivalent to the lifespan
of the worm [22]. Eggs are laid in the small venules
of the portal and perivesical systems. For S. mansoni
and S. japonicum, eggs gradually move towards the
lumen of the intestine and of the bladder and ureters
Tekwu et al. Biomarker Research  (2016) 4:21 Page 2 of 18
for S. haematobium, and are excreted from the body
through feces or urine, respectively [22]. The inter-
mediate host snails are primary for transmission, and
human contact with fresh water that harbors the in-
fective larval form of the parasite known as cercariae
is thus necessary for Schistosome infection [22].
Importance of in vitro drug screening using
Newly Transformed Schistosomula (NTS)
The in vitro culture techniques were developed for para-
sites after the successful establishment of the life cycle of
S. mansoni in the laboratory [15]. The process relied on
adult worms incubated with the candidate drugs for
72 h after which the viability of the parasite is micro-
scopically assessed [15]. This approach of phenotypic
screening using whole worm organism requires the
intensive use of laboratory animals such as hamster, rats
and mice since currently there is no existing in vitro
procedure to generate adult worms. Moreover, this
method is time consuming and low-throughput. It is no
wonder that, in the recent years, researchers are using
the Newly Transformed Schistosomula (NTS) as a tools
for higher-throughput screening for drug sensitivity
assay in the field of antischistosomals drug discovrey
[12, 17–20, 23–27].
The era of working with schistosomula began with the
recovery of mature schistosmulae from the lungs of in-
fected laboratory animals. This was associated with the
inconvenience of recovering only limited worm [19].
The transformation of cercariae into schistosomula
using simple techniques as centrifugation, repeated as-
piration through a syringe needle or chemical stimulation
Fig. 1 Life cycle of Schistosoma (Source: [22])
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was an important discovery in the field of schistosome
cultivation. Nowadays, researchers use cercariae as the
starting material for in vitro studies of schistosomes as
large numbers of schistosomula can be easily obtained in
a manner which is advantageous in economical point of
view [18, 19]. Furthermore and most importantly, the use
of mechanically transformed schistosomulae limits and re-
places the use of live animals in accordance with the 3Rs
(reduce, replace, refine) principles of animal protection.
Using an artificially produced schistosomula in in vitro
drug sensitivity assays might serve as pre-screen tools.
Changes associated with cercariae/
schistosomulum transformation
Schistosoma infection occurs when people get in contact
with free-swimming larval forms of the parasite
(cercariae) released by freshwater snails. Cercariae, with
the aid of its tail swim in the water until they penetrate
the skin of the definitive host during contact with the
contaminated water. From its intermediate snail host to
the definitive host (human), the cercariae undergoes a
series of adaptive changes. All these changes are known
as transformation. During the transformation process,
the tail of cercariae is lost and the secretory glands re-
lease two substances: a mucus which promotes attach-
ment to the skin and enzymes which degrade the skin
[28]. Moreover, on the surface of schistosomula, appears
the transient microvilli and a double unit membrane is
formed on the tegument [29]. Concurrently, some of the
glycocalyx is lost [29]. McLaren and Hockley reported
that in vivo, microvilli are developed on the surface of
schistosomula obtained throughout penetration of the
host skin. This also occurs on schistosomula which have
penetrated a mouse skin prepared in vitro and on artifi-
cial schistosomula prepared by mechanical separation of
the tail from the head of the cercariae [30]. From their
investigation, they reported that microvilli occur at ap-
proximately the same time, have about the same life-
span and show identical morphological characteristics in
each of the three types of schistosomula [30].
Schistosomules rapidly undergo marked physiological
and ultrastructural changes in the body of the definitive
host in order to adapt to the host’s internal environment
[31]. Some of these changes are loss of the glycocalyx,
conversion of trilaminate to heptalaminate tegumental
membrane [29], sensitivity of schistosomula to water
(loss of water tolerance) [28], and evacuation of
secretory glands. All these changes result in the schisto-
somulum stage. Transformation is complete within
about 2–3 h [30, 32]. Brink et al. published in 1977 a
study conducted to compare schistosomula produced ar-
tificially and schistosomula recovered after cercariae had
penetrated isolated skin [33]. They concluded that the
schistosomula prepared by mechanical separation of the
tail from the head of the cercariae fulfill the main cri-
teria of transformation from cercarial to schistosomu-
lum. This is justified by the fact that, the surface
membrane of all type of schistosomula (those mechanic-
ally obtained and those recovered after cercarial penetra-
tion of the isolated skin) had changed from trilaminate
to heptalaminate structures and had loss their cercarial
glycocalyx within 2 h of transformation [33]. They also
reported that in vitro, the development of mechanical
transformed schistosomules is similar to schistosomula
obtained after cercarial had penetrated isolated skin al-
though only 25–50% of mechanically transformed schis-
tosomules reached the ‘gut-closed’ stage by day 12, while
50–70% of skin transformed schistosomules reached this
stage [33]. Thus, 2 mains criteria were generated by the
authors to help decide whether transformation from cer-
cariae to schistosomula has been effective. The 2 cri-
teria were, the NTS must have developed
heptalaminate surface membranes and they must be
capable to growth and develop in vitro, at least to the
‘gut-closed’ stage [33].
Requirement for in vitro drug screening using
NTS
Drugs and chemicals
Praziquantel, mefloquine, auranofin, artesunate, metrifo-
nate, oxamniquine, artemisinins, arthemeter are drugs
used as antischistosomal compounds. These drugs are
usually dissolved in dimethylsulphoxide (DMSO) to ob-
tain drug stock solutions of 10 mg/ml or 10 mM and
then diluted into culture media to serve as positive
control [12, 20, 23, 25, 26, 34]. The highest concen-
tration of DMSO used as drug solvent should not ex-
ceed 1% [15, 18, 24, 34].
Antifungal drug (Amphotericin B) and antibiotic drugs
(penicillin 100 to 300 U/ml and streptomycin 100 to
300 μg/ml) are used to supplement the medium in order
to avoid fungal and bacteria contamination during schis-
tosomula culture [12, 17, 23, 25–27, 34].
Media
Different type of media such as Basch Medium 169
[18–20, 26, 27, 35, 36], Earles’Minimum Essential
Medium [32, 33], Dulbecco’s Modified Eagle’s Medium
(DMEM) [17, 19, 26, 31, 35, 37], Minimum Essential
Medium (MEM) [19, 27, 35], Roswell Park Memorial
Institute (RPMI 1640) [18, 31, 32, 38] and Medium 199
[12, 19, 23–26, 34, 35] have been used in different studies.
Other investigations were developed to compare and ob-
tain optimal culture conditions for the NTS. For the opti-
mal culture condition for schistosomula, several studies
have shown that the supplemented medium is appropri-
ate. Different concentrations of heat inactivated fetal calf
serum (iFCS) 1% [24], 5% [12, 20, 23, 25–27, 34, 38], 10%
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[17, 37], or heat inactivated fetal bovine serum (FBS) 5%
[38], 10% [36] have been used.
The supplemented medium 199 turned out to be the
most suitable medium for the incubation of schistoso-
mula and thus has been widely used for in vitro
screening of others compounds with known activities
against Schistosoma newly transformed schistosomula
[12, 23–25, 34]. Thus 5 to 10% heat inactivated calf
serum is the commonly used supplement by several
researchers.
Snails and cercariae
The snails might be of the genus Bulinus which serves
as the intermediate hosts of S. haematobium as well as
of S. intercalatum or the genus Biomphalaria or Onco-
melania for S. mansoni and S. japonicum respectively.
Snails are individually infected with an average of 10
miracidia per snail [26]. In our laboratory, an average of
5 can be used to successfully infect snails. Usually, snails
are kept in aquarium with dechlorinated water in a
humid room simulating a 12 h day and night cycle.
Intermediate host snails start shedding cercariae from 4
to 6 weeks post-infection with miracidia. According to
the circadian rhythm, each snail species are then col-
lected and placed individually into 24 or 48 well plates
or in a test tube (1 ml of distilled or dechlorinated tap
water/well or per tube). Each test tube or well plate can
be exposed to artificial light for 30 min [39], 1 h [17], or
2 h [40–43]. The cercarial suspension is then collected,
cleaned and concentrated by allowing to stand on ice for
30 to 60 min. During this time, cercariae form into a
mass, settle and adhere to the bottom of the tube. The
supernatant is poured off and replaced with ice-cold dis-
tilled water. This suspension is used for the preparation
of schistosomula. There are several techniques for trans-
forming cercariae into schistosomula and maintaining
them [18, 33, 44–46]. Some of these techniques are per-
formed in vivo and others in vitro. In vivo transform-
ation occurs after host skin penetration [33] and in vitro
transformation can be obtained when parasites penetrate
excised skin [33, 47] or when cercariae tails are removed
mechanically [12, 18–20, 23–25, 27, 33, 34, 45] or chem-
ically [26] and cercariae bodies are incubated in physio-
logical media (Fig. 2).
Newly transformed schistosomula (NTS)
In vitro transformation of Schistosome cercariae to
schistosomula and maintenance
As the schistosomulum stage is becoming attractive for
search of new antischistosomal drugs, this requires the
development of efficient, reproducible and rapid means
to generate large and suitable quantities of the biological
material. The artificial transformation of cercariae into
schistosomula can be induced by various effectors for
instance the cell growth media at 37 °C [48, 49] or low
osmolarity phosphate buffer saline solution [50] that
seem to be able to start off the transformation of cer-
cariae into schistosomula. In vitro, schistosomula can be
obtained through excised skin preparation or by mech-
anical separation of the tail from the body of the cer-
cariae [30]
Non-mechanical transformation
Excised skin preparation of schistosomula Schistoso-
mula can be prepared from cercariae of schistosome by
allowing them to penetrate excised rat [51] or mouse
[52] skins into Hanks' Balanced Salt Solution (HBSS).
The possibility of contamination by host material and
the low yield of produced schistosomula as reported by
Brink et al. [33] make the excised skin penetration tech-
nique inappropriate.
Chemical transformation using glucose The cercarial
transformation can be performed using glucose. This is
known as chemical transformation which is carried out
based on protocol previously described [45]. Briefly, the
cercariae suspension is cooled on ice for 30 min to reduce
parasite motility. Afterwards, the cercariae suspension is
centrifuged for 2 min at 2000 rpm, then resuspended in
5% glucose and incubated for 10 min at 30 °C [26]. The
tails are removed from the bodies using the ice purifica-
tion method as described below.
Mechanical preparation of schistosomula
The mechanical transformation protocol is the most
popular method for obtaining artificially transformed
schistosomula. This method is applied to freshly shed
cercariae and includes centrifugation, passages through
an emulsifying needle, or shaking. The separation of cer-
cariae body from tails is usually done by centrifugation
in a density gradient followed by incubation of the cer-
cariae heads in culture media at 37 °C. In order to de-
tach the tails from the body, these methods usually
incorporate an initial step consisting of agitating the or-
ganisms sufficiently. Schistosomules prepared in vitro
and incubated at 37 °C gradually undergo morphological
and physiological changes [31]. Tucker in 2001 [31] re-
ported that mechanically transformed schistosmula by
24 h in culture, resemble in most respects cercariae that
have penetrated and resided in the skin for about 1 h.
Thus, parasites obtained following this protocol is mor-
phologically or biochemically closed enough to those re-
covered from natural infections [33, 48]. This makes the
mechanical transformation the best alternative method for
large production of schistosomula for high-throughput
studies such as gene expression, identification of drug tar-
gets and identification of effective drugs against schis-
tosmes [37].
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In this paper, we will describe the two of the three
mechanical methods that have been employed for the
acquisition of schistosomules. These include centrifuga-
tion, vortexing, or pressure shearing, such as using the
18-, 20-, 21-, 22-gauge–needle method [31, 37, 43–45].
The double-ended–needle method that presumably was
developed recently, from the normal needle process
seems to be the most widely used for cercariae trans-
formation in vitro [31, 35, 37, 38, 43, 44].
In vitro transformation of cercariae to schistosomula
by vortexing The transformation of cercariae to schisto-
somula by vortexing is performed based on a protocol of
Ramalho-Pinto [45]. Many laboratories used a slightly
adapted Ramalho-Pinto method [19, 26]. Briefly, cercarial
suspension is cooled on ice for 10 min [33], 30–40 min
[26, 31] in order to reduce parasite motility. Then cer-
cariae are further concentrated by centrifuging for 15 s at
1000 rpm [33], 2 min at 100 × g [31], 3 min at 3000 rpm
[26], 4 °C. The supernatant is discarded and the cercarial
pellet is resuspended in cold Hanks` Balanced Salt Solu-
tion (HBSS) containing or not penicillin-streptomycin and
amphotericin B [18, 26], or in 4 °C DMEM or RPMI 1640
[31]. The suspension is vigorously vortexed for 2 min [27],
4 min [26], or 45 s twice separated by ice cooling for
3 min [31] in order to start off tail loss. This step is re-
peated after an incubation of the mixed tail-schistosomula
suspension for 20 min at 37 °C [26]. Tucker [31]
recommended addition of antibiotics if incubation follow-
ing the transformation will be longer than 8 to 12 h.
In vitro transformation of cercariae to schistosomula
by needle and syringe Using a needle and syringe to
separate the tails from the head of cercariae is an equally
valid method for the initial phase of preparing schistoso-
mula. In this case, cercarial suspension is placed into a
plastic centrifuge tube and a syringe with 18-, 20-, 21-,
or 22-gauge–needle is filled. The cercarial suspension is
repeatedly passed through the needle (10–20 times back
and forth) [31, 38, 43–45].
For the double-ended–needle method, an 18-, 20-,
21-, or 22- gauge double-hub, emulsifying needle with
a stabilizing bar is fitted to a sterile 10 ml syringe
[43]. Cercariae are drawn up using a second 10 ml
syringe which is fitted to the open end of the emulsi-
fying needle. The cercariae tails are sheared by ap-
proximately 10–20 passes back and forth through the
needle [31, 37, 38]. This procedure involves manipula-
tion of thousands of cercariae which is an obvious
biohazard. Therefore mandate the use of protective
clothing and gloves, including protection for the face
and the eyes. Afterwards, the schistosomule bodies
are isolated from the sheared tails by Percoll gradient
centrifugation [53] or another purification method as
described below. Table 1 compare the different schis-
tosomula preparation procedure with advantages and
disadvantages.
Fig. 2 Flowchart of Newly Transformed Schistosomula (NTS) Procedure
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Purification of newly transformed schistosomula (NTS)
The schistosomule bodies can be isolated from the
sheared tails by three purification methods which are
Percoll, ice and swirling method.
The Percoll method is based on the method of Lazdins
et al. [53]. The separation of the bodies from the tails is
done on a 70% Percoll gradient (polyvinylpyrolidone-
coated colloidal silica particles) by centrifuging for
15 min at 500 × g, 4 °C [31]. After centrifugation, the
sample is collected from the bottom of the tube and the
collected fraction is then diluted to the culture medium
(RPMI 1640, DMEM, Medium 199, 169, MEM, etc…)
and centrifuged [31, 37, 38]. The schistomula pellet is
resuspended in fresh, warm supplemented medium.
Another purification method of schistosomula is a
swirling technique which is a simple and easy. This
method was described previously [31, 38]. In this case,
schistosomula suspension is poured into a Petri dish
with a sufficient warm medium such as 199 [26], 37 °C
RPMI 1640 complete media [38] or incomplete medium
169 [18]. By swirling the dish gently, all the bodies are
settled in the centre and the lighter tails can be aspirated
and the bodies are left accumulated in the centre. The
bodies (schistosomulae) will be further transferred into
15 or 50 ml centrifuge tubes. This step (swirling and col-
lecting) is repeated until schistosomula are no longer
present in the center of the dish. This objective can be
reached approximately after 4 to 5 times [26] or 10
times [38].
For the ice method, 7 ml of cold HBSS is added to the
schistosomula suspension and cooled on ice for 7 min.
The supernatant is decanted, and the pellet resuspended
again in 7 ml of cold HBSS. This step is repeated three
times. The pellet that contained the recovered schistoso-
mula is then resuspended in pre-warmed (37 °C) supple-
mented Medium 199 [26] or Basch medium [27].
The obtained purified schistosomula are kept in the
schistosmula culture medium and incubate at an atmos-
phere of 37 °C of 5% CO2 for further experiments.
After the purification, the transformation rate and the
purification factor can be estimated. The rate of trans-
formation is estimated by counting the total number of
cercariae in the HBSS suspension before transformation,
and placing them in relation to the total number of
schistosomulae obtained after purification [26]. Marxer
et al. [26] reported a transformation mean rate of
69% for five identically performed mechanical trans-
formations by vortexing and 34% for the chemical
transformation.
To estimate the purification factor, the total number of
bodies and tails are counted in a sample of 50 μl after
the experiment. The ratio is expressed as purification
factor. Marxer et al. [26] after performing the three puri-
fication methods, they calculated the mean purification
factor for each of the methods. The best purification
method according to their analysis is Percoll with purifi-
cation factor of 24.4 ± 11.4 [26]. This method was
followed by the swirling method with a purification fac-
tor of 11.7 ± 3.2 [26]. The ice method presenting a very
weak mean purification factor of 3 ± 1.7 [26].
Schistosomula culture and culture media
Techniques required to cultivate parasites in vitro is a
major area of concern among present day researchers.
Aside the dynamic study and understanding the physi-
ology, behavior and metabolism of parasites, the nature
of the antigenic molecules found in their excretory and
secretory products need to be vigorously pursued and
analyzed upon a successful establishment of the in vitro
culture of the parasite. However, this is a difficult task
since parasites have complex life-cycles comprising dif-
ferent stages and host species requirements. A good
Table 1 Advantages and disadvantages of different ways for preparing schistosomula
Advantages Disadvantages
Mechanical methods (Centrifugation, Syringe
needle method, Vortexing)
Relatively easy and Inexpensive Increased parasite damage
Manipulation of thousands of cercariae Increased risk of infection to researchers
(Potential biohazard to the researcher)
Replaces the use of live animals
Help to obtain large number of schistosomula
Morphological characteristics identical to
schistosmula obtained naturally
Only 25–50% of transformed schistosomula
reach the ‘gut-closed’ stage by day 12
Non-mechanical methods (Chemical
transformation & Excised skin penetration)
Ideal alternative to obtaining high numbers
of viable schistosomula
Significantly less cercariae heads separated
from the tails by chemical method
Simpler
Less damaging to the parasites
Low schistosomula yield and the possibility
of contamination by host material
50–70% of skin transformed schistosomula
reach the ‘gut-closed’ stage by day 12
Require use of live animals (rat, mice,
hamster, …) and skilled technician
Schistosmula are obtained naturally Less appropriate technique for high
throughput
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mention is in the case of parasitic helminths. Tech-
niques involved in parasites culture requires knowledge
of all types of microbiological cultures as different para-
sites demands particular culturing conditions such as
nutrients, temperature and even incubation conditions.
Cultivation of parasites has immense usefulness in the
production of vaccines, testing efficacy of vaccine, and
production of antigens for obtaining serological reagents,
detection of drug-resistance, screening of potential
therapeutic agents and conducting epidemiological stud-
ies. Parasite cultivation is always a challenge. In the case
of schistosoma, transformed schistosomula can be grown
and maintained in vitro in a complex medium [35]. The
growing rate of schistosomules cultured in vitro is not
the same as those in a permissive host, nor will they
become patent adults. Using good and appropriate
methods, about 50% of the cultured parasites will ma-
ture with fully formed guts, and 10% will develop into
sexually distinct male and female worms [31]. Starting
with good number of parasites, a good amount of worms
can be easily maintained and provide a vast quantity of
parasite material for assay. There is also a possibility to
increase the percentage of schistosomules forming guts
and growing properly (50% versus 20%). This can be
achieved by supplementing the growth media with con-
ditioned media during the first week of culture [31].
Using the method described by Tucker et al. [31] with
supplemented DMEM or RPMI1640 media, Schistosoma
spp. schistosomules can be grown in culture media for at
least two months. Abdulla et al. [18] noted that the
Basch Medium 169 is chosen over RPMI for schistoso-
mula culture since worms survive more in the Bash
Medium with 10% mortality for up to 4 weeks whereas
in RPMI medium, an average of 40 to 60% of the para-
sites die within 3 days with continued mortality up to
two weeks . Keiser in 2010 reported that schistosmula
can survive for at least 96 h in different culture media
such as MEM, DMEM, Basch, or TC 199 [19]. Marxer
et al. [26] showed that supplemented Medium 199 is
most suitable for the incubation of schistosomula ob-
tained by transformation in supplemented HBSS. After
undertaken comparison study on three culture media
(DMEM, Medium 199, Basch medium), they reported
that in the supplemented Medium 199, the parasites
were still alive after 120 h with an average viability value
of 2.5 while all schistosomula died by 72 h in Basch
medium and by 144 h in DMEM on the other hand as
shown in Fig. 3 [26]. Schistosomules are cultured at
37 °C in a 5% CO2 incubator [12, 17, 20, 23, 25–27,
31, 34, 37, 43, 45, 54]. It was also shown that over
the course of one week’s incubation, parasites in Basch
Medium 169 appear robust and uniform in shape and ap-
pearance. The effects of culture media on the growth of
schistosomula are summarized in Table 2.
Although the more suitable medium vary from one
study to another, we can observe that studies initiated to
screen compound FDA library [25], Medicines for
Malaria Venture (MMV) box compounds [12],
Mefloquine-related Arylmethanols [34] made used of
supplemented Medium 199. Thus the supplemented
medium 199 seems to be the most suitable medium for
the cultivation of schistosomula and might justify why
it has been widely used for in vitro screening of other
compounds with known activities against Schistosoma
newly transformed schistosomula [12, 23–25, 34].
The biggest obstacle to a successful schistosomules
culture is contamination by fungal and bacterial, which
is mainly due to the fact that the parasites originate from
non-sterile snails. Therefore, the use of antibiotics
(Penicillin and Streptomycin) is useful to prevent
bacteria growth and amphotericin B, a fungizone that
prevent fungal growth. Different concentration as indi-
cated above are used.
In vitro drug sensitivity assays with newly
transformed schistosomula
Schistosomula screening
Schistosoma NTS in vitro Assay is obtained using one
of the transformation methods already described in
this review. The NTS suspension adjusted to a con-
centration of 100 NTS per 50 μL [12, 25, 26, 34] is
then incubated in culture medium at 37 °C, 5% CO2
in ambient air for a minimum of 12 to 24 h to allow
maturation or in order to achieve complete trans-
formation into schistosomula before being further
processed [12, 17, 20, 23–25, 34]. Other authors incu-
bated NTS suspension just for 1 to 3 h before being
used in subsequent experiments [18, 27]. The trans-
formed schistosomula in schistosomula culture medium
are then incubated with the test drugs in a 96-well flat
bottom plate in duplicate or in triplicate and at least 2 to
3 time at a number of 100 NTS/well [12, 20, 25, 26, 34].
Since drug stock solution is prepared in DMSO, the high-
est concentration of DMSO diluted in Schistosomula cul-
ture medium is used to serve as control. Thereafter, drug
effects are assessed microscopically under an inverted
microscope.
Determination of schistosomula viability in response to
test compound
Based on microscope readouts, phenotypic changes of
NTS is recorded at 3 different time points (24 h, 48 h,
72 h post-drug exposure). The changes are recorded
with regard to death of worms, changes in motility, via-
bility and morphological alterations [12, 25, 34]. This
makes use of a viability scale from 0 to 3 (3 =motile, no
changes to morphology; 2 = reduced motility and/or
some damage to tegument noted; 1 = severe reduction to
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motility and/or damage to tegument observed; 0 = dead)
[12, 13, 25–27, 34]. The 50% (IC50) and/or 99% (IC99)
inhibitory concentration are determine for active com-
pounds [12, 23–26, 34].
Inconvenience of microscopic read-out and development
of automated technologies
Current methods utilized to assess schistosomula viabil-
ity encompass microscopic techniques. In this case, the
experimenter manipulates the parasite in vitro and as-
sesses the effect of such manipulation by bright field
examination of morphology. This procedure has been
used in several drug screening protocols [18, 25–27] and
general manipulations of parasite development [55].
Schistosome viability has been assessed in various re-
search work using different criteria. Some of the criteria
are intracellular granularity, schistosomula movement,
schistosomula shape alterations. Nevertheless, evaluating
parasite viability through microscopic read-out are itself
potential deterrents to the development of high through-
put since these methods are slow and subjective and
therefore represent a bottleneck for high-throughput
screening. More often, high throughput methods are
dependent upon assay miniaturisation, objectivity and
very demanding in term of quantification. Several com-
plementary techniques initially developed for single cell
eukaryotes viability measurement have been adapted to
multicellular schistosomes parasites. Among the existing
viability assays that have been developed for use with
single cell eukaryotes, it is amazing to find that only a
limited range of techniques have successfully been trans-
lated to studies with schistosomes. This may be
explained by the multicellular nature of schistosomes
which size more than 1 cm with complex tissue and also
its external tegument bound by a heptalaminate
membrane [56]. The heptalaminate is thought to be
Fig. 3 Survival time of S. haematobium NTS in different culture media (Source: [26])
Table 2 Effects of different culture media on the growth of schistosomula
Culture Media Shape and appearance of NTS Motility of NTS Duration/Viability of NTS
Basch Medium 169 Parasites (NTS) appear robust and uniform High dynamic motility Keeps parasites alive up to one week’s incubation.
Worms survive more with 10% mortality for up
to 4 weeks




Keeps parasites alive up to 144 h
When the culture media is appropriately
supplemented schistosomula can be grown for
at least two months
Medium 199 Generate different degrees of distorted




Supplemented Medium 199 keeps the parasites
alive up to 120 h with an average viability value
of about 2.5
RPMI 1640 Parasites (NTS) rounding Slowed and less
dynamic motility
Parasites degeneration and average death of 40
to 60% within 3 days with continued mortality
up to two weeks
When the culture media is appropriately
supplemented schistosomula can be grown for
at least two months
NTS newly transformed schistosomula, DMEM Dulbecco’s modified eagle’s medium, RPMI Roswell Park Memorial Institute
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selectively permeable to macromolecules, simple com-
pounds and water [57]. Nonetheless, there is a chal-
lenges due to parasite biology, there is also evidence that
some techniques developed for single cell viability can
successfully be adapted to schistosomes.
The size and complexity of schistosomes can partly be
considered as useful attributes for determining viability.
One of the valuable trait in assessing schistosome (both
schistosomula and adult worm schistosome) viability in
vitro is their regular movement, although lack of move-
ment is thought to be not infallible indicator of death.
Motility together with other microscopic characteristics
such as morphology changes, granularity and tegument
damaging [12, 25, 34] are currently the most common
indicators for assessing schistosome viability and repre-
sent the “gold standard” for assessing drug screening
protocols within the schistosomiasis research commu-
nity [12, 18, 20, 25, 34].
Despite the wide application of bright-field, light micro-
scopic assessment of schistosome viability, this technique
presents several problems. Firstly, the personnel should be
well trained to acquire sufficient knowledge on diverse
schistosome phenotypes. Secondly, the bright-field, light
microscopic detection of schistosome viability will always
be subjective due to lack of immunological and molecular
evidence that death has actually occurred when a schisto-
some is immobile. Even when the personnel has acquire
the proficiency at identifying schistosome phenotypes, this
technique is still slow and tedious. For instance a recent
study performed the screening of only 640 potential anti-
schistosomula compounds per month [18]. Finally, repli-
cation of results obtained by bright-field microscopic
means is not always possible, because of the absence of
uniformity between laboratories. With recent advance-
ments in automated technologies, a number of alterna-
tives read-out assay have been attempted with varying
degrees of success in order to avoid the subjective nature
of quantifying viability of schistosome from microscopic
observation of phenotype alone [58]. For example, methy-
lene blue has shown to stain differentially dead schistoso-
mula and therefore was considered as a reliable dye for
dead schistosomula [55] and has been used to assess the
viability of mechanically transformed schistosomula [59].
Regardless, it was thought that vital dyes can be success-
fully translated from single cell viability markers to multi-
cellular schistosomes.
Some fluorescent compounds such as DNA intercalat-
ing dyes, ethidium bromide (EB) and Propidium Iodide
(PI) [60, 61], carboxyfluorescein [61] as well as resazurin
have also been used to quantify schistosome viability in
low-throughput, microscopic read-out methods. In more
detail, resazurin, the active ingredient of Alamar Blue
(AB), a non-toxic and cell permeable compound, is blue
in color and virtually non-fluorescent. But when
resazurin enters the cells, it is converted to resorufin
which is red in color and highly fluorescent. Resazurin is
continuously reduced to resorufin by viable cells. This
staining technique was used to discriminate between live
and dead schistosomula after 48 and 72 h of incubation
with standard selected drug compounds of known anti-
schistosomal activity [26]. Unfortunately this technique
cannot be used for earlier time-points and to measure
dose response drug effects [23].
Ethidium bromide has been used to differentiate dead
schistosomula from live ones during microscopic exam-
ination [61], while PI has successfully been used for the
same reason (as a differential stain of dead schistoso-
mula) for both microscopic examination and flow cy-
tometry [60]. Carboxyfluorescein in contrast to ethidium
bromide and propidium iodide, has been tested as live
staining for schistosomula. However, it was difficult to
clearly differentiate live schistosomula to dead ones since
the latter developed some fluorescence [61].
By promoting the use of single dye staining, a dual
fluorescent viability assay has been developed for schis-
tosomula [17]. In this case, authors combined the use of
PI with fluorescein diacetate (FDA) to easily assess the
percentage of viable schistosomula present in a sample.
By using a microtiter plate reader, this fluorescent bio-
assay was developed for 96 or 384 well microtiter black-
sided, flat-bottom plate optically clear. Ninety-six (96)
well plate were designed for medium throughput and
384 for high throughput applications [17]. The use of
the fluorescent bioassay has the added advantages that it
could increase by 10-fold the number of compounds
screened per month over existing microscope method-
ologies and also, it does not require extensive training of
personnel in parasite morphology [58]. Therefore fluor-
escent bioassay has been shown to be entirely objective
[58] and has been validated with schistosomula. Cur-
rently, there are indications that fluorescent bioassay can
be adapted for use with adult worm schistosomes as well
as other life stages. Although the combined use of PI
and FDA, can objectively and rapidly quantify schisto-
some viability in a high-throughput format, the ability of
PI and FDA to provide significant phenotypic data is
slightly limited [58]. Therefore, there is still a need for
the complementary technologies to the fluorescent
bioassay and methodologies that allow the automated
assessment of phenotype that could be seen as a great
discovery in the field of novel antischistosomal drugs
discovery.
Smout et al. [62] developed a motility assay that was
thought to be one of the technological advance to offer a
solution to this helminth phenotype quantification
challenge, until high content screening as an affordable
reality. This assay, which uses the xCELLigence system
was a new application or device to monitoring cells in a
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Table 3 In vitro drug sensitivity assays developed for the determination of anti-schistosomula activity of drug compounds
Methods Principles Advantages Disadvantages
Microscope readouts without
staining
Parasites are manipulated in vitro and the effect is
assessed by bright field examination of morphology.




- schistosomula shape alterations
This makes use of a viability scale from 0 to 3
- Used to discriminate between live and dead
schistosomula after incubation
- The personnel should be well trained to distinguish
diverse schistosomula phenotypes
- The bright-field, light microscopic detection of
schistosomula viability is subjective due to lack of
immunological and molecular evidence that death
has actually occurred when a schistosomula is
immobile
- The technique is slow (time consuming) and tedious
- Replication of results is not always possible, because
of the absence of uniformity between laboratories
Microscope readouts with Staining
using a single fluorescent dye
Parasites are manipulated in vitro and the effect is
assessed by bright field examination of viable or
dead cells
- Used to discriminate between live and dead
schistosomula after incubation
- Does not require extensive training of personnel
in parasite morphology
- The fluorescent bioassay is objective
- Fluorescent bioassay can be adapted for use
with adult worm schistosomes as well as other
life stages
- Cannot be used for earlier time-points
- Cannot be used to measure dose response drug
effects
- It is sometime difficult to clearly differentiate live
schistosomula from dead ones
Microscope readouts with Staining
using dual fluorescent viability assay
Combination of the use of DNA intercalating dyes
(ethidium bromide (EB), Propidium Iodide (PI)) with
Carboxyfluorescein (fluorescein diacetate), Resazurin
to easily assess the percentage of viable
schistosomula present in a sample
- This bioassay was developed for 96 or 384 well
microtiter plate optically clear
- Designed for medium throughput (96 well) and
high throughput (384 well) applications
- Increase by 10-fold the number of compounds
screened per month over existing microscopy
methodologies
- Does not require extensive training of personnel
in parasite morphology
- The fluorescent bioassay objectively and rapidly
quantify schistosomula viability in a
high-throughput format
- Fluorescent bioassay can be adapted for use
with adult worm schistosomes as well as other
life stages
- The ability of the dual fluorescent dye to provide
significant phenotypic data is slightly limited
Motility assay The assay uses the xCELLigence system for
monitoring cells in a real-time manner. This
technique is based on the detection of changing
electrical currents running through mini gold
electrodes incorporated into the bottom of tissue
culture plates
- Simply and objectively assess anthelmintic
effects by measuring parasite motility in real
time in a fully automated high-throughput
fashion
- Help remove subjectivity in helminth phenotype
characterization
- Results can be compared directly from different
laboratories
- The xCELLigence equipment used in this technology












Table 3 In vitro drug sensitivity assays developed for the determination of anti-schistosomula activity of drug compounds (Continued)
Fluorometric L-lactate assay Consist of the measurement of lactate levels that
reflect clearly the viability of schistosomula and this
also correlate with schistosomula numbers
- Can be used as simple surrogate marker
- Promising new approach to assess the viability
of schistosomula in drug sensitivity assays
- This technique requires that the supernatant must
be removed from the drug assay without aspirating
the schistosomula and the drug assay should be
diluted to an acceptable fluorescence range as
needed. These make the fluorometric L-lactate assay
less than high-throughput
CellTiterGlo® (Commercial
luminescence-based cell viability kit)
Detection of schistosomula viability through
quantitation of ATP
- Suitable for a Medium-Throughput Assay
semi-automated for drug screening
- Fast, highly reliable, sensitive and automation
friendly
- Require a precise multi-drop dispenser to ensure an












Table 4 Summary of the published studies
Objective Media used NTS procedure Outcome Reference
Mansour et al. (2016) screened almost 300,000
compounds using an assay based on motility
of worm, larvae and image analysis of assay
plates
M169 supplemented with 100 U/ml Penicillin,
300 μg/ml Streptomycin, 0.25 μg/ml Fungizone
(Amphotericin B) and 5 % fetal calf serum (FCS)
Mechanical transformation using the
Syringe needle Method
A number of compounds were identified as
promising leads for further chemical
optimization
[54]
Panic et al. (2015a) investigate a panel of
fluorescence/luminescence dyes for their
applicability as viability markers in drug
sensitivity assays for Schistosoma mansoni
schistosomula
Medium 199 supplemented with 5 % heat iFCS
and 1 % penicillin-streptomycin mixture
Mechanical in vitro transformation
(vortexing)
Of the 11 markers selected for testing, resazurin,
Vybrant® and CellTiter-Glo® correlated best with
NTS viability, produced signals ≥ 3-fold stronger
than background noise and revealed a significant
signal-to-NTS concentration relationship
[23]
Panic et al. (2015b) expands the knowledge of
antischistosomal properties of already
approved 1600 FDA compounds from a very
diverse set of indications against Schistosoma
mansoni
Medium 199 supplemented with 5 % heat iFCS
and 1 % penicillin/streptomycin
Mechanical in vitro transformation
(vortexing)
Of the 1600 compounds screened against
schistosomula, 121 were identified as active and
36 of these were active on the adult worms after
Screening. The two in vivo- moderately active
drugs identified in this study, doramectin and
clofazimine present as novel drug classes as
starting points for further investigation
[25]
Lalli et al. (2015) describes the development
and validation of a luminescence based,
medium-throughput assay for the detection
of schistosomula viability through quantitation
of ATP
DMEM complete tissue culture medium Mechanical in vitro transformation
(vortexing)
Schistosomula viability luminescence based assay
is successful and suitable for the identification of
novel compounds potentially exploitable in future
schistosomiasis therapies
Thus representing a valid alternative to
fluorescence-based microscopy assays
[63]
Howe et al. (2015) assessed lactate as a
surrogate marker for viability in Schistosoma
drug screening assays by testing compounds
with reported potencies
Phenol-red free medium 199
Supplemented with 5.5 mM D-glucose,
200 U/ml penicillin, 200 μg/ml streptomycin,
1 % heat iFCS
Mechanically transformed by
vortexing
Lactate levels clearly reflected the viability of
schistosomula and correlated with schistosomulum
numbers. Lactate is a sensitive and simple
surrogate marker to be measured to determine
Schistosoma viability in compound screening
assays
[24]
Ingram-Sieber et al.(2014) investigated the
Medicines for Malaria Venture malaria box
containing 200 diverse drug-like and
200 probe-like compounds with known
antimalarial activity against larval stage of
S. mansoni, followed by testing against adult
worms in vitro and by in vivo studies of lead
candidates
Supplemented Medium 199 with 5 % heat




Underlined the potential of compounds with an
antimalarial background on schistosomes.
Two entirely new chemical scaffolds with
antischistosomal in vitro activity in the sub
micromolar range and moderate in vivo activity
identified
[12]
Protasio et al. (2013) analyzed differences in
gene expression patterns between Mechanical
and Skin Transformed Schistosoma mansoni
Schistosomula and provide enough data to
resolve a long-lasting controversy
Supplemented DMEM, 10 % FCS, 1 % Hepes
buffer with 100 U/L penicillin, 0.1 mg/L
streptomycin and 10 mM L-glutamine
- Mechanical transformation using
the 21G Syringe needle method
- Excised skin from mice
This work contributes to the validation of gene
expression studies that have used Mechanical
transformed schistosomula and provides further
evidence that the MT is a good proxy for natural
skin transformation
[37]
Coultas et al. (2012) compared a current and
widely used double-ended-needle mechanical
transformation method to a culture medium
based on a nonmechanical method
RPMI 1640 medium enriched with L-glutamine;
150 units/ml penicillin, 100 μg/ml streptomycin
and 5 % heat inactivated fetal bovine serum
(iFBS)
Mechanical transformation using the
22-gauge double-ended, luer lok
emulsifying needle
The mechanical and nonmechanical cercariae
transformation methods both yielded significantly













Table 4 Summary of the published studies (Continued)
de Moraes et al. (2012) report the in vitro
antischistosomal activity of piplartine on
S. mansoni schistosomula of different ages
Basch 169 medium containing antibiotics and
supplemented with 10 % fetal bovine serum
(FBS)
Mechanical transformation, using a
Vortex mixer
This report provides the first evidence that
piplartine is able to kill schistosomula of different
ages and reinforce that piplartine is a promising
compound that could be used for the
development of new schistosomicidal agent
[36]
Marxer et al. (2012) developed an in vitro
drug screening assay for S. haematobium
newly transformed schistosomula (NTS).
The cercarial emergence rhythms of the
intermediate hosts of S. mansoni and
S. haematobium, Biomphalaria glabrata and
Bulinus truncatus were studied, two artificial
transformation methods for the production
of the schistosomula were compared and
the best purification method and optimal
culture conditions were established by
testing three different methods and several
different media
Basch Medium 169, DMEM and Medium 199.
All supplemented with 5 % heat iFCS and
200 U/ml penicillin and 200 μg/ml
streptomycin
Mechanical transformation, using a
Vortex mixer and chemical
transformation using glucose
A circadian rhythm existed in both snail species.
The highest transformation rate of S. haematobium
cercariae into NTS was obtained with the vortex
transformation and the highest purification factor
was observed using Percoll. The fluorimetric
readout based on resazurin was very precise in
detecting dead schistosomula
[26]
Ingram et al. (2012) tested mefloquine-related
compounds belonging to the three major
groups of arylmethanols in order to elucidate
their potential as antischistosomal lead
candidates. The selected arylmethanols were
tested against S. mansoni schistosomula and
adults worms in vitro
Medium 199 supplemented with 5 % heat




The study confirmed the high antischistosomal
activity of compounds with a mefloquine scaffold.
Four candidates, WR7930, its two derivatives, and
enpiroline, that are characterized by high
antischistosomal properties in vivo were identified
[34]
Milligan et al. (2011) provide a visual
description of cercarial transformation and
in vitro culturing of schistosomules
RPMI 1640 supplemented with 5 % FBS, 1X
Penicillin/Streptomycin
Mechanical transformation using the
22-gauge double-ended, luer lok
emulsifying needle
This study developed a visual protocols for
in vitro cercarial transformation and
schistosomules culture techniques
[38]
Smout et al. (2010) describe a novel
application for a real-time cell monitoring
device (xCELLigence) that can simply and
objectively assess anthelmintic effects by
measuring parasite motility in real time in
a fully automated high-throughput fashion
RPMI 1640, 1 % antibiotic/antimycotic and
10 mM Hepes
- The study reported that the technique can be
suitable for discovery and development of new
anthelmintic drugs as well as for detection of
phenotypic resistance to existing drugs for the
majority of helminths and other pathogens
where motility is a measure of pathogen viability
[62]
Mansour et al.(2010) report the development
and validation of the Alamar Blue assay
compared with morphology-based
(microscopic) assessment of compound
activity
M169 supplemented with 100 U/ml Penicillin,
100 mg/ml Streptomycin and 5 % FCS
Mechanical transformation using the
Syringe Method
The Alamar Blue assay is readily able to detect
compounds causing death or severe damage
to the larvae but is less reliable than microscopy
for more subtle morphological changes. It is
concluded that an automated high throughput
screen would benefit from integrated use of
both alamar blue and automatic image-based
morphology assays
[20]
Manneck et al.(2010) studied the temporal
effect of this Mefloquine in vitro and in vivo,
and examined alterations on the tegumental
surface of schistosomula and adults of
S. mansoni by means of scanning electron
microscopy (SEM)
Basch medium 169 supplemented with 5 %




Mefloquine induces extensive morphological
and tegumental alterations on both S. mansoni













Table 4 Summary of the published studies (Continued)
Peak et al. (2010) presented a microtiter
plate-based method for reproducibly
detecting schistosomula viability that takes
advantage of the differential uptake of
fluorophores (propidium iodide and
fluorescein diacetate) by living organisms
DMEM lacking phenol red, containing
4500 mg/l glucose, supplemented with
10 % FCS, 2 mM L-glutamine, 200 U/ml
penicillin, 200 mg/ml streptomycin
Mechanically transformation by
vortexing
The study showed that developed method is
sensitive (200 schistosomula/well can be assayed),
relevant to industrial (384-well microtiter plate
compatibility) and academic (96-well microtiter
plate compatibility) settings, translatable to
functional genomics screens and drug assays
[17]
Abdulla et al. (2009) presented a partially
automated, three component phenotypic
screen workflow that utilizes at its apex the
schistosomula stage of the parasite adapted
to a 96-well plate format.
Hits that arise are subsequently screened
in vitro against adult parasites and finally for
efficacy in a murine model of disease
Basch Medium 169 Mechanical transformation using the
22-gauge double-ended, luer lok
emulsifying needle
The study has identified various compounds
and drugs as hits in vitro and leads, with the
prescribed oral efficacy, in vivo
[18]












real-time manner. This was known to simply and object-
ively assess anthelmintic effects by measuring parasite
motility in real time in a fully automated high-
throughput fashion. In principle, this technique is based
on the detection of changing electrical currents running
through mini gold electrodes incorporated into the bot-
tom of tissue culture plates. When schistosomes in the
immature and mature stages are quite dense, they usu-
ally sediment during in vitro culturing and this make
contact with the gold electrodes. It is known that,
changes to the culturing conditions that may impact a
worm’s physiology will probably modifiy its behavior or
phenotype. This result to a measurable fluctuation in
current across the electrodes [58]. Since many anti-
schistosomal drug compounds act by affecting the motil-
ity of the target parasite, the importance of these meas-
urable current fluctuations can be considered as an
indicator of potential therapeutic activity. This biophys-
ical characteristic to assess anthelmintic activity of com-
pounds in real time in a high-throughput fashion was
demonstrated by Smout et al. [62]. This technology was
applied to adult schistosomes to illustrate that by in-
creasing the doses of PZQ, the signal decreased from
adult worm schistosomes, and this allowed to generate a
dose dependent curve. Can this technology be applied to
larval schistosome life stages? Although the answer to
this question is currently unknown, it appears feasible. It
is believed that this assay may provide an advanced
methodology to microscopy that will help remove sub-
jectivity in helminth phenotype characterization as well
as making available a technology to compare results dir-
ectly from different laboratories [58]. But the original
cost of the xCELLigence equipment may restrict its
widespread use.
Howe et al. [24] investigated a fluorometric L-lactate
assay for viability in schistosoma drug screening assays.
Lactate is a by-product of glycolysis. It is secreted via
aquaglyceroporins from NTS and adult worm schisto-
somes [23]. Authors fully investigated parameters of lac-
tate measurement and performed drug sensitivity assays
by applying schistosomulae and adult worms to establish
a proof of concept. They showed that lactate levels re-
flect clearly the viability of schistosomula and this was
also correlated with schistosomulae numbers. They
tested compounds with described potencies, and com-
pared activities of fluorometric L-lactate assay with mi-
croscopy. Howe et al. [24] concluded that lactate can be
used as simple surrogate marker since its measurement
can be a promising new approach to assess the viability
of schistosomulae in drug sensitivity assays. However,
this technique requires two things. Firstly, the super-
natant must be removing from the drug assay without
aspirating the Schistosomula and secondly, the drug
assay should be diluted to an acceptable fluorescence
range as needed. These two aspects make the fluoromet-
ric L-lactate assay less than high-throughput [23].
More recently, the commercial luminescence-based
cell viability kit known as CellTiterGlo® was validated by
Lalli et al. [63] for the in vitro assay using S. mansoni
NTS and adult worms schistosomes. In this procedure
unfortunately, a precise multi-drop dispenser is required
to ensure an exact number of NTS present in each well.
Although the investigation of marker-dye based assays
has been a popular activity, we can simply note that, the
aim of a simple, inexpensive and accurate dye that does
not require much additional equipment or analysis has
not so far been entirely met [23]. Table 3 summarizes
different in vitro drug sensitivity assays developed so far
for the determination of anti-schistosomula activity of
drug compounds. The summary of publications cited in
this review are contained in Table 4.
Conclusion
One of the great deal of new drug discovery against
schistosomes is dependent on in vitro whole parasite
screens. Access to adequate quantities and a substantial
source of whole parasite organisms is a constant source
of concern. Thus mechanically transformed schistoso-
mula may be used as alternative for the purpose of high-
throughput tools in the field of antischistosomal drugs
discovery. This may help for the rapid discovery of ur-
gently needed new drugs that will be useful in the con-
trol of schistosmiasis which represent one of the major
devastating parasitic infections. Although it is clear from
recent publications that subjective measures of NTS via-
bility, motility and phenotype are still the gold standard,
none of the automated assessment of phenotype have so
far been validated.
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